Unveiling Tomorrow’s Cancer Solutions: A Deep Dive into Radiopharmaceuticals, Dosimetry, and AI Integration

In this webinar, the expert speakers will focus on the reasons for the increase in demand for radiopharmaceuticals and dosimetry for tailoring cancer treatment; current challenges in clinical trials and deficiencies presented in the current dosimetry regulatory guidelines and protocols; and advancements in routine clinical dosimetry driven by emerging technologies such as artificial intelligence (AI)-driven dosimetry methods.

While the trajectory of radiopharmaceutical dosimetry is promising, challenges persist within the clinical trial landscape. Deficiencies in existing guidelines from regulatory bodies such as the US Food and Drug Administration (FDA), European Association of Nuclear Medicine (EANM) and Foundation for the National Institutes of Health (FNIH) pose hurdles that need addressing.

For cancer treatment, the growing interest in radiopharmaceuticals and dosimetry is evident. The increasing demand for personalized medicine applications and their impact on clinical outcomes suggests a rising need for tailored dosage and treatment for each patient’s cancer profile.

Register today to gain insights into clinical trials of radiopharmaceuticals and the possibility of AI-driven dosimetry methods in the future.

Speakers

Jon DeVries, MBA, Chief Executive Officer, Mirada Medical

Jon DeVries has more than 20 years of experience spearheading the creation and release of innovative cloud-based healthcare initiatives that bring advanced services and technologies to providers and researchers, with the goal of improving patient care. Prior to joining Mirada, as CEO of Qlarity Imaging, Jon was responsible for executing the company’s vision to transform breast imaging through diagnostic AI technology, starting with its initial product QuantX — the first FDA-cleared diagnostic AI software. Jon has earned eight patents in the areas of superconducting electronics, medical imaging, and AI. His contributions to the medical imaging community have resulted in several awards, including being named an AI Activator by The Imaging Wire and one of the Top 50 Tech Visionaries by InterCon.

Message Presenter

Mark Crockett, MD, Chief Medical Officer, Mirada Medical; President, TeleDaaS

Dr. Mark D. Crockett, MD, FACEP has been in HCIT leadership for more than 20 years, with Chief Medical Officer positions at Optum, Best Doctors, and Picis. He has led organizations in several areas of healthcare software, including electronic medical records, population health, and most recently patient safety and compliance. During much of that time, he practiced Emergency Medicine at Advocate Healthcare in Chicago. He is a published author in the Journal of the American Medical Association and holds several patents in healthcare information systems.

Message Presenter

Jess Guarnaschelli, MD, Senior Medical Director, Medical Department, Medpace

Dr. Jess Guarnaschelli is board-certified by the American Board of Radiology in Radiation Oncology, Radiation Biology and Radiation Physics. She brings more than twenty years of experience in clinical research, academia, and clinical radiation oncology. Dr. Guarnaschelli is well-versed in Phase I radiopharmaceutical clinical trial design having worked with many radioisotopes, radiopharmaceuticals, and solid tumor indications. Prior to joining Medpace, Dr. Guarnaschelli served at the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center. During her academic and clinical career, she focused on novel treatments and innovative imaging techniques for patients with solid malignancies. She was the principal investigator (PI) on numerous clinical trials and received several funding awards. Dr. Guarnaschelli has held nationally recognized leadership positions and is a frequently invited speaker at national and international conferences. She has served on boards and advisory committees, remaining active in several that are focused on radiation initiatives.

Message Presenter

Daphnée Villoing, PhD, Dosimetry Specialist and Senior Project Manager, Medpace Core Labs

Daphnée Villoing is a physicist with 13 years of expertise in the dosimetry of diagnostic and therapeutic nuclear medicine. She obtained a PhD in radiophysics and medical imaging, with postdoctoral training at the National Institutes of Health. Her research program was mainly dedicated to building dosimetry methods for clinical or epidemiological applications in the field of nuclear medicine, but she also participated in pioneer research on ultra-high dose rates irradiations in proton therapy. Her experience of academic medical research led to 23 publications in peer-reviewed journals and more communications in international conferences. She is a member of the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging. Daphnée Villoing is currently the Project Manager of several Phase I-II radiopharmaceutical clinical trials involving radioactive pharmacokinetics and dosimetry assessments. She regularly provides scientific input for Medpace and Medpace Core Labs studies.

Message Presenter